Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979597 | 0.96 | CYP3A4 (0.45) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL14782070 | 0.89 | MEN1 (0.41) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL20049675 | 0.89 | LPAR3 (0.42) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL19979590 | 0.88 | CYP3A4 (0.44) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL21725375 | 0.84 | MEN1 (0.43) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL20045049 | 0.82 | LPAR3 (0.54) | LPAR3LPAR1LPAR2 | |
| Trolamine SCHEMBL28296634 | 0.81 | CYP3A4 (0.65) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL530398 | 0.81 | CYP2C9 (0.56) | GAAMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL14778154 | 0.81 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR1LPAR2GAA | |
| SCHEMBL14790946 | 0.80 | MEN1 (0.51) | GAAMEN1KMT2ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149226-B2 | Preparation and use of aminoalkylphosphonic acid dialkyl ester compounds in a lubricant for antiwear, friction reduction, and/or micropitting prevention | AFTON CHEMICAL CORPORATION (US) | 2021-10-19 | — | — | US | claimed |
| US-11149226-B2 | Preparation and use of aminoalkylphosphonic acid dialkyl ester compounds in a lubricant for antiwear, friction reduction, and/or micropitting prevention | AFTON CHEMICAL CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| EP-2570471-B1 | Aminoalkylphosphonic acid dialkyl ester compounds in a lubricant for antiwear and/or friction reduction | AFTON CHEMICAL CORP (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200181522-A1 | Preparation and Use of Aminoalkylphosphonic Acid Dialkyl Ester Compounds in a Lubricant for Antiwear, Friction Reduction, and/or Micropitting Prevention | AFTON CHEMICAL CORP (US) | 2020-06-11 | — | — | US | disclosed |
| US-10563146-B2 | Preparation and use of aminoalkylphosphonic acid dilakyl ester compounds in a lubricant for antiwear, friction reduction, and/or micropitting prevention | AFTON CHEMICAL CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20130072407-A1 | PREPARATION AND USE OF AMINOALKYLPHOSPHONIC ACID DILAKYL ESTER COMPOUNDS IN A LUBRICANT FOR ANTIWEAR, FRICTION REDUCTION, AND/OR MICROPITTING PREVENTION | AFTON CHEMICAL CORPORATION (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2570471-A1 | Preparation and use of aminoalkylphosphonic acid dialkyl ester compounds in a lubricant for antiwear and/or friction reduction | Afton Chemical Corporation (US) | 2013-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072407-A1 | PREPARATION AND USE OF AMINOALKYLPHOSPHONIC ACID DILAKYL ESTER COMPOUNDS IN A LUBRICANT FOR ANTIWEAR, FRICTION REDUCTION, AND/OR MICROPITTING PREVENTION | TP53RK, MDK, DEK | CYP3A4 4619/4885LPAR3 1148/4885LPAR1 1045/4885 |
| US-11149226-B2 | Preparation and use of aminoalkylphosphonic acid dialkyl ester compounds in a lubricant for antiwear, friction reduction, and/or micropitting prevention | TP53RK, PHOSPHO1, PTAFR | CYP3A4 4748/4885LPAR3 1317/4885LPAR1 1170/4885 |
| US-20200181522-A1 | Preparation and Use of Aminoalkylphosphonic Acid Dialkyl Ester Compounds in a Lubricant for Antiwear, Friction Reduction, and/or Micropitting Prevention | TP53RK, PHOSPHO1, PTAFR | CYP3A4 4748/4885LPAR3 1317/4885LPAR1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.